- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05340634
Evaluation of Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With PCOS.
Evaluation of the Efficacy of the Combination of Antioxidants Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With Polycystic Ovary Syndrome: A Prospective Randomized Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain
- Hospital Quironsalud San José
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Women newly diagnosed with PCOS with at least 2 of the following symptoms:
- Oligo/Anovulation < 21 or > 35 days > 90 days (any cycle) < 8 periods / year
- Hyperandrogenism (clinical symptoms or laboratory results)
Polycystic ovary morphology (NHMRC guideline): In any ovary:
20 follicles* and/or ovarian volume greater than or equal to 10ml and no corpus luteum, cysts or dominant follicles
*number of follicles per ovary measuring 2-9 mm
- > 18 years old
- Overweight defined as BMI>25
- Normal prolactin levels
- Women with altered coagulation factors or a personal history of thromboembolism for whom OAC is contraindicated (they will be included in the control group without randomization)
- Written inform consent
Exclusion Criteria:
- Diabetic women
- Adrenal enzyme deficiency and/or other endocrine disease
- Pregnant or lactating women.
- Women under treatment with SNRIs (serotonin reuptake inhibitors)
- Other serious illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Oral Contraceptive
Drospirenone 4 mg once a day for 6 months
|
Drospirenone 4 mg once a day
|
EXPERIMENTAL: Oral Contraceptive + Food supplement Metionac
Drospirenone 4 mg once a day and Metionac twice daily (200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 Vitamin B6) for 6 months
|
Drospirenone 4 mg once a day
Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
|
OTHER: Food supplement MetioNac
Metionac twice daily (200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 Vitamin B6) for 6 months
|
Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in the Mean BMI at 6 Months
Time Frame: 6 months
|
Evolution of Body Mass Index in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean Insuline level at 6 Months
Time Frame: 6 months
|
Evolution of Insuline level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean Glucose level at 6 Months
Time Frame: 6 months
|
Evolution of Glucose level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean Triglycerides at 6 Months
Time Frame: 6 months
|
Evolution of Triglycerides level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean HDL at 6 Months
Time Frame: 6 months
|
Evolution of high-density lipoprotein (HDL) cholesterol level in patients with PCOS after 6 months therapy.
|
6 months
|
Change from Baseline in the Mean LDL at 6 Months
Time Frame: 6 monhts
|
Evolution of low-density lipoprotein (LDL) level in patients with PCOS after 6 months therapy
|
6 monhts
|
Change from Baseline in the Mean AST at 6 months
Time Frame: 6 months
|
Evolution of aspartate aminotransferase (AST) level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean ALT at 6 months
Time Frame: 6 months
|
Evolution of alanine aminotransferase (ALT) level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean GGT at 6 months
Time Frame: 6 months
|
Evolution of gamma glutamyltransferase (GGT) level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean Bilirubin at 6 Months
Time Frame: 6 months
|
Evolution of total and free bilirubin level in patients with PCOS after 6 months therapy
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in the Mean 17 beta estradiol at 6 months Translate from: English volume_up 20 / 5,000 Translation results Change from baseline in the Mean 17 beta estradiol at 6 Months
Time Frame: 6 months
|
Evolution of 17 beta estradiol level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean 17 hydroxy progesterone at 6 months Translate from: English volume_up 20 / 5,000 Translation results Change from baseline in the Mean 17 beta estradiol at 6 Months
Time Frame: 6 months
|
Evolution of 17 hydroxy progesterone level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean LH at 6 months Translate from: English volume_up 20 / 5,000 Translation results Change from baseline in the Mean 17 beta estradiol at 6 Months
Time Frame: 6 months
|
Evolution of luteinizing hormone (LH) level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean FSH at 6 months Translate from: English volume_up 20 / 5,000 Translation results Change from baseline in the Mean 17 beta estradiol at 6 Months
Time Frame: 6 months
|
Evolution of follicle-stimulating hormone (FSH) level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean Testosterone at 6 months
Time Frame: 6 months
|
Evolution of testosterone level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean Androstenedione at 6 months
Time Frame: 6 months
|
Evolution of androstenedione level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean DHEA at 6 months
Time Frame: 6 months
|
Evolution of Dehydroepiandrosterone (DHEA) level in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean TSH at 6 months
Time Frame: 6 months
|
Evolution of thyroid stimulating hormone (TSH) level in patients with PCOS after 6 months therapy.
|
6 months
|
Change from Baseline in the Mean Homocysteine at 6 months
Time Frame: 6 months
|
Evolution of homocysteine (HC) level in patients with PCOS after 6 months therapy.
|
6 months
|
Change from Baseline in the Mean HOMA-IR at 6 months
Time Frame: 6 months
|
Evolution of HOMA insulin resistance level in patients with PCOS after 6 months therapy.
|
6 months
|
Change from Baseline in the Mean Hb A1c at 6 months
Time Frame: 6 months
|
Evolution of hemoglobin A1c in patients with PCOS after 6 months therapy.
|
6 months
|
Change from Baseline in the Mean SHBG at 6 months
Time Frame: 6 months
|
Evolution of sex hormone binding globulin in patients with PCOS after 6 months therapy.
|
6 months
|
Change from Baseline in the Mean Hirsutism score at 6 months
Time Frame: 6 months
|
Evolution of hirsutism score measured by Ferriman - Gallwey scale in patients with PCOS after 6 months therapy.
The Ferriman-Gallwey scale for hirsutism.
A score of 1 to 4 is given for nine areas of the body.
A total score less than 8 is considered normal, a score of 8 to 15 indicates mild hirsutism, and a score greater than 15 indicates moderate or severe hirsutism.
A score of 0 indicates absence of terminal hair.
|
6 months
|
Change from Baseline in the Mean Acne self-assessment score at 6 months
Time Frame: 6 months
|
Evolution of acne self assessed from 1 to 10 (1 minimum severity, 10 maximum severity) in acne severity level in 3 areas: face, neck, back in patients with PCOS after 6 months therapy.
|
6 months
|
Change from Baseline in the Mean Alopecia score at 6 months
Time Frame: 6 months
|
Evolution of alopecia using Ludwig scale in patients with PCOS after 6 months therapy.
The Ludwig hair loss scale illustrates progressive hair loss patterns in women.
It ranges from I to III.
Stage I begins with thinning on the top of the head.
In stage II the scalp starts to show.
All of the hair at the crown of the head may be lost when the hair loss progresses to stage III.Stage I begins with thinning on the top of the head.
In stage II the scalp starts to show.
All of the hair at the crown of the head may be lost when the hair loss progresses to stage III.
|
6 months
|
Change from Baseline in the Proportion of patients with irregular menstrual cycle at 6 months
Time Frame: 6 months
|
Regularization of irregular menstrual cycle in patients with PCOS after 6 months therapy
|
6 months
|
Change from Baseline in the Mean Migraine score at 6 months
Time Frame: 6 months
|
Evolution of migraine score using Migraine Disability Assessment test (MIDAS) in patients with PCOS after 6 months. The MIDAS score is derived as the sum of missed days due to a headache over a 3-month period in the three domains: school work or work for pay; household work or chores; and family, social, and leisure activities. The four-point grading system for the MIDAS questionnaire is as follows: • Grade 1 (scores ranging from 0 to 5): little or no disability Grade 2 (scores ranging from 6 to 10): mild disability Grade 3 (scores ranging from 11 to 20): moderate disability Grade 4 (21 or greater): severe disability. |
6 months
|
Change from Baseline in the Mean QoL score at 6 months
Time Frame: 6 months
|
Evolution of quality of life score using Health-Related Quality of Life Questionnaire for women with Polycystic Ovary Syndrome (adapted from PCOSQ qustionnaire) in patients with PCOS after 6 months therapy.
The PCOS HRQL questionnaire represents a new measure for women with PCOS and includes five domains: emotional, body hair, infertility, weight, and menstrual problems.
A shorten version with 19 questions was used.
It ranges from 0 (no impact on quality of life to 114 maximum negative impact in the patient´s quality of life.
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Endocrine System Diseases
- Disease
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Polycystic Ovary Syndrome
- Syndrome
- Physiological Effects of Drugs
- Reproductive Control Agents
- Contraceptive Agents, Female
- Contraceptive Agents
- Contraceptives, Oral
Other Study ID Numbers
- SOP-DIET
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Ovary Syndrome
-
Cairo UniversityCompleted
-
Alexandria UniversityRecruitingPolycystic Ovary Syndrome (PCOS)Egypt
-
Saudi German Hospital - MadinahCompletedPolycystic Ovary Syndrome (PCOS)Saudi Arabia
-
University of CopenhagenCompletedPolycystic Ovary Syndrome (PCOS)Denmark
-
Odense University HospitalCompleted
-
Poznan University of Medical SciencesUniversity of California, DavisUnknownPolycystic Ovary Syndrome (PCOS)Poland
-
Assaf-Harofeh Medical CenterUnknownInfertility | Polycystic OvariesIsrael
-
Riphah International UniversityCompleted
-
Dexa Medica GroupCompletedPolycystic Ovary Syndrome (PCOS)Indonesia
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedPolycystic Ovary Syndrome (PCOS)United States
Clinical Trials on Oral contraceptive
-
University of Southern CaliforniaUnited States Department of DefenseCompleted
-
University of Southern CaliforniaUnknownOral ContraceptiveUnited States
-
Federal University of Rio Grande do SulHospital de Clinicas de Porto Alegre; Coordenação de Aperfeiçoamento de Pessoal... and other collaboratorsCompletedPolycystic Ovary Syndrome
-
Clinic of Phlebology and Laser Surgery, Chelyabinsk...RecruitingChronic Venous DiseasesRussian Federation
-
Kayseri Education and Research HospitalCompletedAdverse Effect of Oral Contraceptives, Subsequent Encounter
-
Universidad Vina del MarCompletedContraceptive Usage | Diffuse Noxious Inhibitory ControlChile
-
Penn State UniversityMassachusetts General Hospital; Purdue UniversityCompletedBone; Disorder, Development and GrowthUnited States
-
Teva Women's HealthCompletedOral Contraceptive | HemostasisUnited States, Italy